Literature DB >> 11240849

Insulin resistance adds to endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension.

B Zizek1, P Poredos.   

Abstract

OBJECTIVES: To evaluate whether endothelium-dependent (nitric oxide-mediated) dilation of the brachial artery (BA) is impaired in patients being treated for essential hypertension (EH), and whether this abnormality can be detected in normotensive offspring of subjects with EH (familial trait, FT); and to investigate the interrelationship between flow-mediated vasodilation (FMD) and hyperinsulinaemia/insulin resistance.
DESIGN: Cross-sectional study.
SETTING: Angiology department at a teaching hospital.
SUBJECTS: The study encompassed 172 subjects, of whom 46 were treated hypertonics aged 40-55 (49) years, and 44 age-matched, normotensive volunteers as controls. We also investigated 41 normotonics with FT aged 20-30 (25) years and 41 age-and sex-matched controls without FT. MAIN OUTCOME MEASURES: Using high-resolution ultrasound, BA diameters at rest, during reactive hyperaemia (endothelium-dependent dilation) and after sublingual glyceryl trinitrate (GTN) application (endothelium-independent dilation) were measured.
RESULTS: In hypertonics FMD was significantly lower than in controls [2.4 (2.9) vs. 7.4 (2.5)%; P < 0.00005], as was GTN-induced dilation [12.1 (4.3) vs. 16.1 (4.6)%; P=0.0007]. In subjects with FT, FMD was also decreased compared with the control group [5.8 (4.1) vs. 10.0 (3.0)%; P < 0.00005]. The response to GTN was comparable in both groups of young subjects. FMD was negatively related to insulin concentration in all subjects studied (P < 0.00005).
CONCLUSIONS: In treated patients with EH, flow-mediated dilation of the BA as well as endothelium-independent dilation are decreased. In individuals with FT the endothelial function of the peripheral arteries is also altered in the absence of elevated blood pressure. Endothelial dysfunction is related to hyperinsulinaemia/insulin resistance, which could be one of the pathogenetic determinants of EH and its complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240849     DOI: 10.1046/j.1365-2796.2001.00794.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

Review 1.  Hypertension and insulin disorders.

Authors:  Michinori Imazu
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

2.  Microvascular reactivity in lean, overweight, and obese hypertensive adolescents.

Authors:  Péter Monostori; Akos Baráth; Ildikó Fazekas; Eszter Hódi; Adrienn Máté; Ildikó Farkas; Zsuzsanna Hracskó; Ilona S Varga; Viktória Sümegi; Balázs Gellén; Csaba Bereczki; Sándor Túri
Journal:  Eur J Pediatr       Date:  2010-06-16       Impact factor: 3.183

3.  Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.

Authors:  Michael P Dubé; Jude Christopher Gorski; Changyu Shen
Journal:  Cardiovasc Toxicol       Date:  2008-01-03       Impact factor: 3.231

4.  High-fat meals do not impair postprandial endothelial function in HIV-infected and uninfected men.

Authors:  Gretchen E Volpe; Christine A Wanke; Cindy M Imai; Kevin S Heffernan; Jeffrey T Kuvin; Alexandra Mangili
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06-26       Impact factor: 2.205

5.  Biological correlates of day-to-day variation in flow-mediated dilation in individuals with Type 2 diabetes: a study of test-retest reliability.

Authors:  S G West; P Wagner; S L Schoemer; K D Hecker; K L Hurston; A Likos Krick; L Boseska; J Ulbrecht; A L Hinderliter
Journal:  Diabetologia       Date:  2004-09-09       Impact factor: 10.122

6.  Increased Insulin following an Oral Glucose Load, Genetic Variation near the Melatonin Receptor MTNR1B, but No Biochemical Evidence of Endothelial Dysfunction in Young Asian Men and Women.

Authors:  Maria A Matuszek; Angelyn Anton; Sobana Thillainathan; Nicola J Armstrong
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.